Clinical effect of NABs in MS patients treated with interferon beta
| Study | Study period | Placebo | NABs− | NABs+ | p Value | |
|---|---|---|---|---|---|---|
| Betaferon/Betaseron27 | Phase III RRMS | 2 years | 1.06 | 0.56 | 1.08 | 0.001 |
| Attack rate: | ||||||
| Avonex19 | Phase III RRMS | 2 years | 1.6 (82) | 0.5 (63) | 1.7 (18) | 0.062 |
| MRI–Gd lesions: mean (n) | ||||||
| Rebif25 | PRISMS Extension | 4 years | ||||
| Attack rate | NA | 0.5 | 0.81 | 0.002 | ||
| T2–active lesions | NA | 0.3 | 1.4 | <0.001 | ||
| Change in T2 volume from baseline | NA | −8.5% | +17.6% | <0.001 |